Skip to main content
PMC home page
Experimental and Therapeutic Medicine logoLink to Experimental and Therapeutic Medicine
. 2017 Oct 17;14(6):6207–6212. doi: 10.3892/etm.2017.5323

MicroRNA-520a suppresses the proliferation and mitosis of HaCaT cells by inactivating protein kinase B

Rui Wang 1, Zigang Zhao 1, Liqiang Zheng 1, Xiaojing Xing 1, Wei Ba 1, Junfen Zhang 1, Min Huang 1, Wenwei Zhu 1, Bing Liu 1, Xianfu Meng 1, Jia Bai 1, Chengxin Li 1, Hengjin Li 1,✉
PMCID: PMC5740736  PMID: 29285178

Abstract

Psoriasis is a chronic inflammatory disease of the skin for which an effective treatment strategy remains to be developed. Characteristics of psoriasis include an altered differentiation of keratinocytes and hyperplasia of the skin. The present study aimed to investigate the role served by miR-520a in psoriasis. The results demonstrated that miR-520a inhibited the proliferation of HaCaT cells. miR-520a directly regulated the mRNA and protein expression of its target gene, protein kinase B (AKT). The siRNA silencing of AKT expression in these cells was also evaluated. miRNA-520a repressed the proliferation and mitotic entry of HaCaT cells, and promoted cell apoptosis. AKT silencing suppressed the proliferation of HaCaT cells. These results suggest that miRNA-520a regulates the survival of HaCaT cells by inhibiting AKT expression. miRNA-520a and AKT may therefore be novel targets for the treatment of patients with psoriasis.

Keywords: microRNA, psoriasis, proliferation, mitosis, keratinocytes

Introduction

Psoriasis is a chronic inflammatory disease of the skin that affects 0.1–3% of the population worldwide (1,2). Characteristics of the disease include altered differentiation of keratinocytes and hyperplasia of the skin (1). Common treatments for psoriasis include herbal therapy and systemic, topical, combination and phototherapy treatments, which inhibit excessive keratinocyte proliferation (3). Although there are a variety of therapies available to treat psoriasis, no cure has been developed and the relapsing-remitting nature of psoriasis continues to adversely affect patient quality of life (4,5). The pathophysiology of psoriasis is not well understood. Genetic and auto-immunological mechanisms are suspected, but no single unified theory exists to explain the nature of the disease.

MicroRNAs (miRNAs) are a group of small, non-coding RNAs that are 22–25 nucleotides long and post-transcriptionally regulate gene expression (6). miRNAs control gene expression by pairing with incompletely matching target sites of the 3′-untranslated regions (3′UTRs) of mRNAs, causing translational repression and/or mRNA destabilization, thereby downregulating the expression of the targeted gene. There are an increasing number of studies on the vital function of miRNAs in regulating expression at the post-transcriptional level. There has been a focus on the role of miRNAs in numerous biological progressions, including inflammatory disorders (7), and a variety of miRNAs are regarded as a novel category of inflammatory mediators in human diseases (8–11).

The transcription factor E2F transcription factor 2 is downregulated by miR-520a, which subsequently suppresses the cell cycle progression and proliferation of hepatoma cells (12). Glabridin (GLA) is a novel antitumor medicine that suppresses inflammation, proliferation and oxidization in cancer cells. miR-520a promotes the antitumor role of GLA by inhibiting the nuclear factor (NF)-κB signalling pathway and GLA upregulates the expression of miR-520a. miR-520a combines with the 3′UTR of the NF-κB p65 subunit and inhibits its expression (13). Wang et al (14) demonstrated that miR-520a may be a key regulator of endoplasmic reticulum (ER) stress and the proliferation of Raji cells (human B lymphoma cell line), and may be associated with the PRKR-like ER kinase/eukaryotic translation initiation factor 2 subunit α and protein kinase B (AKT1)/NF-κB signalling pathways. miR-520a specifically binds to the 3′UTR of AKT1 mRNA, and is a crucial mediator for inhibiting proliferation of Raji cells. Therefore, the use of miR-520a may be a potential therapeutic strategy for treating Burkitt's lymphoma.

In vitro studies on the differentiation of keratinocytes are hindered due to the inherent properties of keratinocytes and the limitations of the stringent requirements for their culture (15). Primary keratinocytes have a finite life span, while transformed cell lines exhibit many phenotypic features not found in normal cells (15). HaCaT cells are spontaneously immortalized human keratinocytes, which have been widely used based on their near normal phenotype and easy propagation (15). They have been used previously as a model for epidermal keratinocytes in the study of multiple diseases, including psoriasis (16). The present study demonstrated that miR-520a suppresses HaCaT cell proliferation.

Treatment strategies for psoriasis remain elusive. The phosphatidylinositol 3-kinase (PI3K)/AKT pathway has recently been identified to be associated with psoriasis (17). AKT was predicted as the target gene of miR-520a in the present study and AKT may serve a crucial role in the proliferation of HaCaT cells. Therefore, the present study highlights a potential method to suppress the proliferation of HaCaT cells with miR-520a through the AKT pathway.

Materials and methods

Cell line

The HaCaT cell line was purchased from NTCC (cat. no. 340383; Biovector Science Lab, Inc., Beijing, China). HaCaT cells were used for an in vitro model of psoriasis and cultured in Dulbecco's modified Eagle's medium (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% fetal bovine serum (Invitrogen; Thermo Fisher Scientific, Inc.), penicillin and streptomycin. The cells were cultured at 37°C with 5% CO2.

Reagents

Lipofectamine 2000, the mirVana miRNA Isolation kit and the TaqMan miRNA assay kit were obtained from Thermo Fisher Scientific, Inc. The Luc-Pair™ miR Luciferase Assay kit (cat. no. S900042) for detecting the 3′-UTR luciferase reporter gene of AKT was obtained from SwitchGear Genomics (Menlo Park, CA, USA). The assay kits for cell proliferation (BrdU Assay kits) were purchased from Promega Corporation (Madison, WI, USA). The control small interfering (si)RNA (cat. no. sc-37077) and anti-AKT siRNA (cat no. sc-38910) were both obtained from Santa Cruz Biotechnology Inc. (Dallas, TX, USA). The mimics of human miR-520a were purchased from Applied Biosystems (cat. no. KIT 001168; Thermo Fisher Scientific, Inc.), and the scramble miRNA as negative control (cat. no. SI03650325) and inhibitors (cat. no. GS574467) were purchased from Qiagen China Co., Ltd. (Shanghai, China). The miR-520a mimics and inhibitors were transfected based on the manufacturer's instructions for Lipofectamine 2000.

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis

Total RNA was extracted from cultured HaCaT cells with TRIzol® (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's instructions, and RT was then performed using the Access Quick RT-PCR system (Promega Corporation, Madison, WI, USA) at 44°C for 1 h followed by 92°C for 10 min. RT-qPCR analysis was conducted using the ABI 7,500 Real-Time PCR system (Applied Biosystems; Thermo Fisher Scientific, Inc.). Thermocycling conditions were as follows: 2 min at 95°C followed by 30 to 32 cycles of 30 sec at 94°C, 30 sec at 58°C and 30 sec at 72°C, with a final extension for 10 min at 72°C. GAPDH was used as an internal control and results were quantified using the 2−∆∆Cq method (18). GAPDH was used as the control. The primer sequences were as follows: AKT forward, 5′-TGGACTACCTGCACTCGGAGAA-3′ and reverse, 5′-GTGCCGCAAAAGGTCTTCATGG-3′; GAPDH forward, 5′-GTCTCCTCTGACTTCAACAGCG-3′ and reverse, 5′-ACCACCCTGTTGCTGTAGCCAA-3′.

Western blot analysis

Total protein was extracted from lysed cells with radioimmunoprecipitation assay buffer (Cell Signaling Technology, Inc., Danvers, MA, USA) and the protein concentrations were measured using a BCA Protein Assay (Pierce; Thermo Fisher Scientific, Inc.). Equivalent amounts of protein (20 µg/well) were separated by 10% SDS-PAGE. Following electrophoretic transfer of the proteins to a nitrocellulose membrane, the membrane was blocked for 1 h at 22°C with 5% dried milk. The membrane was incubated with primary antibodies (dilution 1:2,000) overnight at 4°C followed by secondary antibodies in 5% dried milk for 1 h at 22°C. Primary antibodies were as follows: β-actin (sc-58673) and anti-AKT (sc-24500) (both from Santa Cruz Biotechnology, Inc.). The secondary antibodies, rabbit anti-mouse IgG (Light Chain Specific; D3V2A) and mAb (no. 58802; both 1:5,000) were obtained from Cell Signaling Technology, Inc. Protein bands were detected using an enhanced chemiluminescence detection kit (GE Healthcare Life Sciences, Little Chalfont, UK).

Luciferase reporter assays

miRNA-target prediction software DIANA microT (http://diana.imis.athena-innovation.gr/DianaTools/index.php?r=microtv4/index; version 4.0) was used to predict the 3′UTR targets of miR-520a, 5′-AAUAAAAGUGACUUGAGCACUUA-3′, which were then amplified by PCR with the Geneamp XL PCR kit (Thermo Fisher Scientific, Inc.) using DNA extracted from HaCaT cells and subsequently cloned into pmirGLO plasmids. The thermocycling conditions of PCR were as follows: 5 min at 95°C followed by 25 cycles of 30 sec at 94°C, 30 sec at 55°C and 1 min at 72°C, with a final extension for 10 min at 72°C. The following primers were used: forward, 5′-CUCAGGCUGUGACCCUCCAGAGGGAAGUACUUUCUGUUGUCUG-3′ and reverse, 5′-GAGUUUGGCUUUGUCAGGUUUCCCUUCGUGAAAGAAAAGAGAG-3′ (Invitrogen; Thermo Fisher Scientific, Inc.). The pmirGLO-3′-UTR of AKT construct plasmids and the control were transfected into cells using Lipofectamine 2000 according to the manufacturer's instructions. The activity of luciferase was then analyzed with a dual-luciferase reporter system (cat. no. E1910, Dual-luciferase assay system; Promega Corporation) following transfection for 48 h. Signals from reporter genes were normalized to Renilla luciferase.

Bromodoexyuridine (BrdU) assays and mitotic index analysis

Cells were synchronized for 16 h using the block method with double thymidine (19). Cells were then released and collected, or fixed for assays, 1 ml of Carnoy's fixative (3 parts methanol, 1 part glacial acetic acid) at −20°C for 20 min. DNA synthesis or mitotic entry analysis was performed using the BrdU-fluorescein isothiocyanate (FITC) labeling method (20). Cells were counted using an immunofluorescence microscope and then the number of BrdU-FITC-positive cells was quantified. The fluorescence excitation and emission wavelengths were set to 488 and 525 nm, respectively.

Mitotic events were determined using Hoechst 33258 DNA staining for 5 min at 37°C and time-lapse video microscopy. Following synchronization, real-time images of the cells were obtained at 10 min intervals. Mitotic events in the cells were detected by changes in morphology. Mitotic cells were counted based on DNA condensation and nuclear morphology.

Detection of apoptosis

HaCaT cells fluorescently stained for 15 min at room temperature with Annexin V-FITC/propidium iodide (PI) from MitoCapture Apoptosis Detection kit (BioVision, San Francisco, CA, USA) were analyzed using a flow cytometer at 12, 24, 36 and 48 h following treatment with miR-520a mimics or inhibitors. Annexin V-FITC and PI were excited by the 488 or 532 nm laser emitted at wavelengths >610 nm. The flow cytometry (FCS) filter was used to filter the data files. The program has been designed to gate out microbead populations and remove debris and other unnecessary events from the FCS data files that may interfere with the clustering procedure of the FCAP Array software. The filtering process is based on a gate defined by the user. The gate should be defined on a single FCS data file and the FCS Filter program will automatically apply the same gate for all FCS files in a selected folder. The software saves the filtered events into new FCS 2.0 data files and keeps the original files. Data analysis was performed using FlowJo software version 7.6.3 (FlowJo LLC, Ashland, OR, USA).

Statistical analysis

Continuous variables were determined to be normally distributed using SPSS software (version 18.0; SPSS, Inc., Chicago, IL, USA). Data are expressed as the mean ± standard deviation from three independent experiments. A unpaired Student's t-test or one-way analysis of variance and post hoc pairwise multiple comparisons tests were used for the comparisons of multiple groups. Data with a non-normal distribution were analyzed using the Kruskal-Wallis test. P<0.05 was determined to indicate statistically significant difference.

Results

miR-520a inhibits the expression of AKT in HaCaT cells

DIANA microT software was used to identify the targets of miR-520a in HaCaT cells. The 3′UTR of AKT mRNA was identified as a potential target of miR-520a (data not shown). It was then demonstrated that the luciferase activity of the AKT 3′UTR was significantly reduced in miR-520a treated HaCaT cells compared with the control group (P<0.001; Fig. 1A). Western blotting then revealed that miR-520a notably inhibited the expression of AKT in HaCaT cells (Fig. 1B).

Figure 1.

Figure 1.

Open in a new tab

miR-520a inhibits the expression of AKT in HaCaT cells. (A) Relative luciferase activity of the 3′UTR of AKT in HaCaT cells. (B) Western blot analysis of the expression of AKT in the control, NC and HaCaT cells transfected with miR-520a. **P<0.01 vs. the control group. NC, negative control; miR, microRNA; UTR, untranslated region; AKT, protein kinase B.

miR-520a suppresses the mitotic entry and proliferation of HaCaT cells

The role served by miR-520a in HaCaT cells was further investigated using a BrdU assay (Fig. 2). The results indicated that miR-520a significantly suppressed the proliferation (P<0.05; Fig. 2A) and mitotic entry (P<0.05; Fig. 2B) of HaCaT cells in a time-dependent manner, while the inhibitors of miR-520a promoted the proliferation (P<0.05; Fig. 2A) and mitotic entry (P<0.01; Fig. 2B) of HaCaT cells compared with the control group.

Figure 2.

Figure 2.

Open in a new tab

miR-520a inhibits the mitotic entry and proliferation of HaCaT cells. The percentage of (A) BrdU positive cells and (B) mitotic cells in the NC, HaCaT, miR-520a inhibitor and miR-520a mimic groups following transfection. *P<0.05, **P<0.01 vs. the NC group. NC, negative control; miR, microRNA; BrdU, bromodeoxyuridine.

miR-520a induces HaCaT cell apoptosis

Flow cytometry was used to measure the apoptosis induced by miR-520a mimics and inhibitors (Fig. 3). The mimics of miR-520a significantly increased HaCaT cell apoptosis in a time-dependent manner, while the inhibitors of miR-520a repressed HaCaT cell apoptosis (all P<0.05 vs. the control group). These results indicate that miR-520a suppresses the survival of HaCaT cells.

Figure 3.

Figure 3.

Open in a new tab

miR-520a promotes the apoptosis of HaCaT cells. Flow cytometry analysis of Annexin V and propidium iodide stained HaCaT cells. *P<0.05, **P<0.01 vs. the NC group. NC, negative control; miR, microRNA.

The function of AKT in HaCaT cell proliferation and mitosis

AKT is a key regulatory factor of cell proliferation (21). In the present study, the expression of AKT was knocked down in a HaCaT cell model via siRNA silencing. The expression of AKT was examined using western blot analysis and RT-qPCR. The proliferation and mitosis of HaCaT cells were then detected. The results confirmed that specific siRNAs for AKT induced significant downregulation of AKT mRNA expression compared with the untransfected HaCaT cell group or the siRNA control group, respectively (Fig. 4A; P<0.01). Furthermore, the protein expression of AKT was downregulated by siRNA (Fig. 4B). In addition, the decreased expression of AKT in HaCaT cells significantly suppressed the proliferation and mitosis of HaCaT cells in a time-dependent manner (Fig. 4C and D; all P<0.05 vs. the siRNA control group).

Figure 4.

Figure 4.

Open in a new tab

siRNA silencing of AKT represses the proliferation and mitosis of HaCaT cells. Following the transfection of HaCaT cells with AKT-specific siRNA, the expression of AKT mRNA and protein was analyzed using (A) reverse transcription-quantitative polymerase chain reaction and (B) western blotting analyses, respectively. (C) The proliferation of HaCaT cells was determined at 12, 24, 36 and 48 h following transfection using a BrdU assay. (D) The percentage of mitotic HaCaT cells were determined at 10, 12, 14, 16 and 18 h following transfection. *P<0.05, **P<0.01 vs. the siRNA control group; miR, microRNA; AKT, protein kinase B; siRNA, small interfering RNA.

Discussion

Psoriasis is a long-lasting autoimmune disease. Its primary clinical feature is skin injury, where the skin appears scaly, red and itchy. The severity of psoriasis varies from its presence in a small area to coverage of the entire body (22). The Koebner phenomenon is when Psoriatic changes occur depending on the location of skin lesions (23). Skin lesions may be pustular, guttate, erythrodermic, inverse or plaque (22). They are commonly located on the scalp, around the navel, shin and the back of the forearms (24,25). Genetic factors associated with the immune reaction of skin cells serve a role in the pathogenesis of psoriasis, which may be affected by the environment, psychological stress or infections (22–24). However, the mechanisms of the pathogenesis of psoriasis remain unclear; therefore, further study is required. Furthermore, cardiovascular disease, lymphomas, psoriatic arthritis, depression and Crohn's disease may increase the risk of psoriasis (24).

There are no effective treatments for psoriasis; however, various therapies may be used to improve its symptoms (24), including ultraviolet light, vitamin D3 cream and immune system suppressing medications, such as methotrexate and steroid creams (22,26). Genetic susceptibility serves a crucial role in the development of psoriasis (27,28). The majority of genes associated with psoriasis have been identified as serving a role in the immune system, particularly in T cells and major histocompatibility complexes (29). Genomic research may potentially be used to identify the molecular mechanisms and pathways involved in psoriasis, as well as potential novel drug targets.

Classic genome-wide linkage analysis has indicated that there are nine loci on different chromosomes associated with psoriasis, including those containing genes whose products serve a role in inflammation, such as AKT (29–32). These loci are associated with the NF-κB and tumor necrosis factor (TNF)-α signaling pathways (29). In addition, T lymphocytes induce the abnormal proliferation of keratinocytes, which may trigger psoriasis (29).

During inflammation, TNF-α regulates its downstream molecules, including the transcription factors AKT or NF-κB, and controls several cellular pathophysiological progressions (30). The crucial role served by AKT in cell proliferation and mitosis has been demonstrated previously (33). AKT is activated by a range stimuli and regulates multiple steps in angiogenesis, including invasion, migration and cell survival. The phosphorylation of AKT and the inhibition of the PI3K-AKT signaling pathway act upstream of NF-κB, leading to its activation in acute inflammatory responses (34). However, the endogenous miRNA-dependent mechanisms of silencing AKT expression in HaCaT cells remain unknown. Thus, the present study investigated the upstream mechanisms of AKT activation associated with miRNA regulation.

The present study demonstrated that miR-520a inhibits the proliferation and mitotic entry of the human keratinocyte cell line HaCaT. Furthermore, AKT was identified as a predicted target gene of miRNA-520a. A luciferase reporter assay was then used to confirm that miR-520a directly binds with the 3′UTR of AKT. The results indicated that in the 3′UTR of AKT, the relative luciferase activities were significantly decreased in HaCaT cells transfected with miR-520a. This confirmed that miR-520a directly regulates the expression of its target gene, AKT, at the mRNA and protein level.

miRNAs are non-coding RNAs that influence gene expression. They do this through mediating post-transcriptional gene silencing by suppressing the translation of mRNAs or degrading mRNAs. miRNAs serve a role in a variety of cellular processes, including differentiation, development, proliferation and tumorigenesis (35).

The present study aimed to investigate the role served by miR-520a in regulating the proliferation and mitosis of the human keratinocyte cell line HaCaT. The results indicated that miR-520a directly regulates the expression of AKT, and significantly inhibits the mitotic entry and proliferation of HaCaT cells, while promoting apoptosis. Furthermore, the proliferation and mitotic entry of HaCaT cells was increased in a time-dependent manner by inhibiting miR-520a, and HaCaT apoptosis was inhibited. These results demonstrate that miR-520a suppresses HaCaT cell survival.

Knockdown of AKT was established in a HaCaT cell model via transfection with siRNAs specific for AKT. The results indicated that the expression of AKT was significantly downregulated, which significantly inhibited the mitotic entry and proliferation of HaCaT cells.

The present study only investigated one member of the PI3K-AKT-mammalian target of rapamycin kinase system; therefore, the regulation of the entirety of this cascade system by miRNA-520a remains unclear. Additionally, further investigation into the other effects of miRNA-520a in psoriasis, including its effect on NF-κB, TNF-α and ER-stress is required. The challenges of using miRNA-520a as a treatment for patients with psoriasis may be solved by using mimics of miRNA-520a or siRNA specific for AKT.

In conclusion, the results of the present study indicate that miRNA-520a induces the downregulation of AKT expression, and suppresses the proliferation and mitotic entry of the human keratinocyte cell line HaCaT via the AKT signalling pathway. Thus, miRNA-520a and AKT may be a novel target for the treatment of psoriasis.

Acknowledgements

The present study was supported by the National Natural Science Foundation of China (grant no. 30600524; Beijing, China).

References

  • 1.Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361:496–509. doi: 10.1056/NEJMra0804595. [DOI] [PubMed] [Google Scholar]
  • 2.Gudjonsson JE, Elder JT. Psoriasis: Epidemiology. Clin Dermatol. 2007;25:535–546. doi: 10.1016/j.clindermatol.2007.08.007. [DOI] [PubMed] [Google Scholar]
  • 3.Rahman M, Alam K, Ahmad MZ, Gupta G, Afzal M, Akhter S, Kazmi I, Jyoti, Ahmad FJ, Anwar F. Classical to current approach for treatment of psoriasis: A review. Endocr Metab Immune Disord Drug Targets. 2012;12:287–302. doi: 10.2174/187153012802002901. [DOI] [PubMed] [Google Scholar]
  • 4.Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, Lebwohl M, Koo JY, Elmets CA, Korman NJ, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58:826–850. doi: 10.1016/j.jaad.2008.02.039. [DOI] [PubMed] [Google Scholar]
  • 5.Garshick MK, Kimball AB. Psoriasis and the life cycle of persistent life effects. Dermatol Clin. 2015;33:25–39. doi: 10.1016/j.det.2014.09.003. [DOI] [PubMed] [Google Scholar]
  • 6.Ambros V. The functions of animal microRNAs. Nature. 2004;431:350–355. doi: 10.1038/nature02871. [DOI] [PubMed] [Google Scholar]
  • 7.Bartel DP. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–297. doi: 10.1016/S0092-8674(04)00045-5. [DOI] [PubMed] [Google Scholar]
  • 8.Esteller M. Non-coding RNAs in human disease. Nat Rev Genet. 2011;12:861–874. doi: 10.1038/nrg3074. [DOI] [PubMed] [Google Scholar]
  • 9.Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microRNA targets. Cell. 2003;115:787–798. doi: 10.1016/S0092-8674(03)01018-3. [DOI] [PubMed] [Google Scholar]
  • 10.He L, Hannon GJ. MicroRNAs: Small RNAs with a big role in gene regulation. Nat Rev Genet. 2004;5:522–531. doi: 10.1038/nrg1415. [DOI] [PubMed] [Google Scholar]
  • 11.Esquela-Kerscher A, Slack FJ. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer. 2006;6:259–269. doi: 10.1038/nrc1840. [DOI] [PubMed] [Google Scholar]
  • 12.Dong Y, Zou J, Su S, Huang H, Deng Y, Wang B, Li W. MicroRNA-218 and microRNA-520a inhibit cell proliferation by downregulating E2F2 in hepatocellular carcinoma. Mol Med Rep. 2015;12:1016–1022. doi: 10.3892/mmr.2015.3516. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Juan M, Shilong N, Xingxing W, Lu S, Fei J, Yuan L, Zhong L. The repressive effect of miR-520a on NF-κB/IL-6/STAT-3 signal involved in the glabridin-induced anti-angiogenesis in human breast cancer cells. RSC Advances. 2014;5:34257–34264. [Google Scholar]
  • 14.Wang X, Wang P, Zhu Y, Zhang Z, Zhang J, Wang H. MicroRNA-520a attenuates proliferation of Raji cells through inhibition of AKT1/NF-κB and PERK/eIF2α signaling pathway. Oncol Rep. 2016;36:1702–1708. doi: 10.3892/or.2016.4975. [DOI] [PubMed] [Google Scholar]
  • 15.Deyrieux AF, Wilson VG. In vitro culture conditions to study keratinocyte differentiation using the HaCaT cell line. Cytotechnology. 2007;54:77–83. doi: 10.1007/s10616-007-9076-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Breitkreutz D, Schoop VM, Mirancea N, Baur M, Stark HJ, Fusenig NE. Epidermal differentiation and basement membrane formation by HaCaT cells in surfacetransplants. Eur J Cell Biol. 1998;75:273–286. doi: 10.1016/S0171-9335(98)80123-4. [DOI] [PubMed] [Google Scholar]
  • 17.Coppo R, Camilla R, Alfarano A, Balegno S, Mancuso D, Peruzzi L, Amore A, Canton Dal A, Sepe V, Tovo P. Upregulation of the immunoproteasome in peripheral blood mononuclear cells of patients with IgA nephropathy. Kidney Int. 2009;75:536–541. doi: 10.1038/ki.2008.579. [DOI] [PubMed] [Google Scholar]
  • 18.Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T). Method. Methods. 2001;25:402–408. doi: 10.1006/meth.2001.1262. [DOI] [PubMed] [Google Scholar]
  • 19.Kumagai-Sano F, Hayashi T, Sano T, Hasezawa S. Cell cycle synchronizationn of tobacco BY-2 cells. Nat Protoc. 2006;1:2621–2627. doi: 10.1038/nprot.2006.381. [DOI] [PubMed] [Google Scholar]
  • 20.Lei Y, Liu H, Yang Y, Wang X, Ren N, Li B, Liu S, Cheng J, Fu X, Zhang J. Interaction of LHBs with C53 promotes hepatocyte mitotic entry: A novel mechanism for HBV-induced hepatocellular carcinoma. Oncol Rep. 2012;27:151–159. doi: 10.3892/or.2011.1489. [DOI] [PubMed] [Google Scholar]
  • 21.Fu X, Wen H, Jing L, Yang Y, Wang W, Liang X, Nan K, Yao Y, Tian T. MicroRNA-155-5p promotes hepatocellular carcinoma progression by suppressing PTEN through the PI3K/Akt pathway. Cancer Sci. 2017;108:620–631. doi: 10.1111/cas.13177. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Meier M, Sheth PB. Clinical spectrum and severity of psoriasis. Curr Probl Dermatol. 2009;38:1–20. doi: 10.1159/000232301. [DOI] [PubMed] [Google Scholar]
  • 23.Khurrum H, AlGhamdi KM, Bedaiwi KM, AlBalahi NM. Multivariate analysis of factors associated with the koebner phenomenon in vitiligo: An observational study of 381 patients. Ann Dermatol. 2017;29:302–306. doi: 10.5021/ad.2017.29.3.302. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386:983–994. doi: 10.1016/S0140-6736(14)61909-7. [DOI] [PubMed] [Google Scholar]
  • 25.Sima J. Dermatology: Illustrated Study Guide and Comprehensive Board Review. Springer; New York: 2012. pp. 83–87. ISBN: 978-3-319-47395-6. [Google Scholar]
  • 26.Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team: Global epidemiology of psoriasis: A systematic review of incidence and prevalence. J Invest Dermatol. 2013;133:377–385. doi: 10.1038/jid.2012.339. [DOI] [PubMed] [Google Scholar]
  • 27.Tamparo CD, Lewis MA. Diseases of the Human Body. 5th edition. F.A. Davis Company; Philadelphia, PA: 2011. p. 180. ISBN-13: 978-0-8036-2505-1. [Google Scholar]
  • 28.Krueger G, Ellis CN. Psoriasis-recent advances in understanding its pathogenesis and treatment. J Am Acad Dermatol. 2005;53(Suppl 1):S94–S100. doi: 10.1016/j.jaad.2005.04.035. [DOI] [PubMed] [Google Scholar]
  • 29.Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361:496–509. doi: 10.1056/NEJMra0804595. [DOI] [PubMed] [Google Scholar]
  • 30.Yamamoto S, Yamane M, Yoshida O, Okazaki M, Waki N, Toyooka S, Oto T, Miyoshi S. Activations of mitogen-activated protein kinases and regulation of their downstream moleculesafter rat lung transplantation from donors after cardiac death. Transplant Proc. 2011;43:3628–3633. doi: 10.1016/j.transproceed.2011.09.075. [DOI] [PubMed] [Google Scholar]
  • 31.Smith CH, Barker JN. Psoriasis and its management. BMJ. 2015;333:380–384. doi: 10.1136/bmj.333.7564.380. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Prieto-Pérez R, Cabaleiro T, Daudén E, Ochoa D, Roman M, Abad-Santos F. Genetics of Psoriasis and Pharmacogenetics of Biological Drugs. Autoimmune Dis. 2013;2013:613086. doi: 10.1155/2013/613086. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Beaudoin GM. Mosaic cellular patterning in the nose: Adhesion molecules give their two scents. J Cell Biol. 2016;212:495–497. doi: 10.1083/jcb.201602023. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Choi EK, Jang HC, Kim JH, Kim HJ, Kang HC, Paek YW, Lee HC, Lee SH, Oh WM, Kang IC. Enhancement of cytokine-mediated NF-kappaB activation by phosphatidylinositol 3-kinase inhibitors inmonocytic cells. Int Immunopharmacol. 2006;6:908–915. doi: 10.1016/j.intimp.2006.01.007. [DOI] [PubMed] [Google Scholar]
  • 35.Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: Are the answers in sight? Nat Rev Genet. 2008;9:102–114. doi: 10.1038/nrg2290. [DOI] [PubMed] [Google Scholar]

Articles from Experimental and Therapeutic Medicine are provided here courtesy of Spandidos Publications

RESOURCES